Inotropes in Acute Heart Failure

 

Inotropes in Acute Heart Failure: A Practical Guide

Introduction

Acute heart failure (AHF) is a life-threatening condition characterized by inadequate cardiac output and/or elevated filling pressures leading to pulmonary and systemic congestion. While diuretics and vasodilators remain the cornerstone of treatment, inotropes are reserved for patients with evidence of low cardiac output, hypoperfusion, or cardiogenic shock.

Current guidelines emphasize that inotropes should be used only when clearly indicated because they increase the risk of arrhythmias, myocardial ischemia, and mortality.

---

When Are Inotropes Indicated?

Guideline-Based Indications

Use inotropes in patients with:

Cardiogenic shock

Persistent hypotension (SBP <90 mmHg)

Evidence of end-organ hypoperfusion:

Cold extremities

Altered mental status

Oliguria

Elevated lactate

Low cardiac output despite adequate filling pressures

Failure to respond to diuretics and vasodilators

Not Recommended

Routine use in:

Stable acute heart failure

Congestion without hypoperfusion

Patients with preserved perfusion ("warm and wet")

---

Commonly Used Inotropes

1. Dobutamine

Mechanism

Predominantly β1 agonist

Mild β2-mediated vasodilation

Increases contractility and heart rate

Dose

2–20 mcg/kg/min

Hemodynamic Effects

↑ Cardiac output

↓ Filling pressures

Mild ↓ SVR

Advantages

Rapid onset

Easy titration

Preferred in low-output states without severe hypotension

Disadvantages

Tachyarrhythmias

Increased myocardial oxygen consumption

Reduced effectiveness in patients on beta-blockers

Best Use

Cardiogenic shock with normal or mildly reduced blood pressure

---

2. Milrinone

Mechanism

Phosphodiesterase-3 inhibitor

Increases intracellular cAMP independently of β-receptors

Dose

0.125–0.75 mcg/kg/min

Loading dose generally avoided in shock

Hemodynamic Effects

↑ Contractility

↑ Cardiac output

Significant vasodilation

Advantages

Effective despite beta-blocker therapy

Useful in pulmonary hypertension

Reduces pulmonary vascular resistance

Disadvantages

Hypotension

Ventricular arrhythmias

Accumulates in renal dysfunction

Best Use

Advanced HFrEF receiving beta-blockers

Right ventricular failure with pulmonary hypertension

---

3. Dopamine

Mechanism

Dose-dependent effects:

Dose Main Effect

1–3 mcg/kg/min Dopaminergic

3–10 mcg/kg/min β1 stimulation

>10 mcg/kg/min α1 vasoconstriction

Hemodynamic Effects

↑ Heart rate

↑ Contractility

↑ Blood pressure

Disadvantages

High arrhythmia risk

Inferior outcomes compared with norepinephrine in shock

Current Role

Limited

Consider only in patients with marked bradycardia and hypotension

---

4. Levosimendan

Mechanism

Calcium sensitizer

Opens ATP-sensitive potassium channels

Hemodynamic Effects

Increased contractility

Vasodilation

Minimal increase in oxygen consumption

Advantages

Effective despite beta-blockade

Long-lasting active metabolites

Disadvantages

Hypotension

Not universally available

Best Use

Advanced heart failure

Patients receiving beta-blockers

---

Inopressor Agents

Patients with severe cardiogenic shock often require both inotropic and vasopressor support.

Norepinephrine

Mechanism

Predominantly α1 agonist

Mild β1 stimulation

Effects

↑ Mean arterial pressure

Maintains coronary perfusion

Current Guideline Preference

First-line vasopressor in cardiogenic shock.

Often combined with:

Dobutamine

Milrinone

---

Choosing the Right Agent

Clinical Scenario Preferred Agent

Low output, normal BP Dobutamine

On beta-blockers Milrinone or Levosimendan

RV failure with pulmonary hypertension Milrinone

Cardiogenic shock with hypotension Norepinephrine + Dobutamine

Bradycardia with hypotension Dopamine

Bridge to LVAD/transplant Milrinone or Levosimendan

---

Monitoring During Inotrope Therapy

Monitor:

Blood pressure

Heart rate

Urine output

Lactate

Renal function

Continuous ECG

Electrolytes

Signs of ischemia

Targets:

MAP ≥65 mmHg

Improving urine output

Declining lactate

Improved mentation

Warm extremities

---

Major Risks of Inotropes

Arrhythmias

Atrial fibrillation

Ventricular tachycardia

Ventricular fibrillation

Myocardial Ischemia

Increased oxygen demand

Hypotension

Particularly with milrinone and levosimendan

Increased Mortality

Prolonged use associated with worse long-term outcomes

Therefore, use the lowest effective dose for the shortest duration possible.

---

Key Exam Pearls

Inotropes are indicated for hypoperfusion, not merely congestion.

Dobutamine is the most commonly used inotrope in acute heart failure.

Milrinone works despite beta-blockade and reduces pulmonary vascular resistance.

Norepinephrine is the preferred vasopressor in cardiogenic shock.

Dopamine has a higher arrhythmia rate and a limited modern role.

Long-term inotrope use is associated with increased mortality.

"Cold and wet" patients are the classic group requiring inotropic support.

Take-Home Message: 

Inotropes are lifesaving in acute heart failure with low cardiac output and hypoperfusion but should be reserved for carefully selected patients because their benefits come at the cost of increased arrhythmic and mortality risk. Current guidelines favor norepinephrine for shock and either dobutamine or milrinone for inotropic support depending on blood pressure, beta-blocker use, and right ventricular involvement.